Thelial Technologies, founded in 2009, is a pioneering company in the biotechnology sector, focused on the discovery and development of therapies targeting carcinoma. Their mission, encapsulated in their slogan, is "Discovering and developing targeted carcinoma therapies through innovative drug discovery and repositioning for advancing novel cancer treatments."
The company's core innovation is their proprietary platform, theLiTE™ (Thelial – Live Targeted Epithelia), which has proven effective in identifying carcinoma-targeted drugs. Through a comprehensive screening of over 1200 candidates, they have successfully pinpointed six promising drug candidates. This breakthrough approach not only validates theLiTE™ but also facilitates the repositioning of existing drug compounds to explore new therapeutic applications.
In its pursuit of advancing cancer treatment, Thelial is simultaneously formulating a new class of treatment aimed at targeting actin within cancer cells. Despite its last financial injection of €50.00K as a grant from EASME - EU Executive Agency for SMEs in December 2016, the company demonstrates a sustained commitment to innovation in healthcare solutions.
